US5166143A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
Assignee: ER Squibb and Sons LLC
•
Filing: 1991-06-13
•
Granted: 1992-11-24
•
Expires: 2011-06-13
Abstract
Abstract A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering an ACE inhibitor such as fosinopril or ceranapril, prior to, during and/or after angioplasty.
Inventors
- 👤 Miguel A. Ondetti
- 👤 A. K. Gunnar Aberg
- 👤 Patricia Ferrer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:43
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/55; A61K38/556; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/66; A61K31/675
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
56 words
A method for preventing or reducing the risk of restenosis following angioplasty, which comprises administering to a mammalian specie in need of such treatment of an effective amount of a phosphorus-containing angiotensin converting enzyme inhibitor selected from the group consisting of phosphonate substituted amino acid, phosphonate substituted imino acid, phosphinylalkanoyl proline, phosphinylalkanoyl substituted proline and phosphonamidate.
Claim 2
Independent Claim
56 words
A method for preventing or reducing the risk of restenosis following angioplasty, which comprises administering to a mammalian specie in need of such treatment of an effective amount of a phosphorus-containing angiotensin converting enzyme inhibitor selected from the group consisting of phosphonate substituted amino acid, phosphonate substituted imino acid, phosphinylalkanoyl proline, phosphinylalkanoyl substituted proline and phosphonamidate.
Claim 3
Independent Claim
21 words
The method of claim wherein said phosphorus-containing angiotensin converting enzyme inhibitor is selected from the group consisting of fosinopril and ceranapril.
Claim 4
Independent Claim
16 words
The method defined in claim wherein the angiotensin converting enzyme inhibitor is administered prior to angioplasty.
Claim 5
Dependent Claim
17 words
The method as defined in claim 1 wherein the angiotensin converting enzyme inhibitor is administered during angioplasty.
Claim 6
Dependent Claim
17 words
The method as defined in claim 1 wherein the angiotensin converting enzyme inhibitor is administered after angioplasty.
Claim 7
Dependent Claim
32 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 0.1 to about 500 mg/one to four times daily.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-24 | 1996-05-25 | 1996-11-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-24 | 2000-05-25 | 2000-11-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-24 | 2004-05-25 | 2004-11-24 | $7700.00 | Window Closed / Lapsed |